4-(6-Aminopyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester CAS:571188-59-5

4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester, often abbreviated in research, is being investigated for diverse therapeutic uses. This compound's intricate structure includes heterocyclic rings and functional groups designed to interact with specific biological targets implicated in diseases. In pharmaceutical research, its application focuses on potential therapeutic benefits. The compound's structural elements, such as the bromo and cyclopentyl groups and the pyrido[2,3-d]pyrimidine core, enhance its pharmacological profile by potentially influencing receptor binding or enzymatic activity crucial for disease pathways. Researchers are particularly interested in evaluating its efficacy in preclinical models for conditions like neurodegenerative disorders, cancer, and infectious diseases. The 1,1-dimethylethyl ester modification contributes to stability and bioavailability, crucial for effective delivery and sustained activity in biological systems. Ongoing studies aim to elucidate its pharmacokinetic and pharmacodynamic properties for optimized dosage regimens and reduced adverse effects. Development involves rigorous testing for safety, efficacy, and compatibility with existing treatments, requiring collaboration between medicinal chemists, pharmacologists, and clinical researchers to advance towards clinical trials and regulatory approval. In summary, 4-[6-[(6-Bromo-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinecarboxylic acid 1,1-dimethylethyl ester shows promise in pharmaceutical research, poised to address medical needs through innovative pharmacotherapy approaches.